Oura has acquired Doublepoint, a company that specialises in gesture recognition for wearables. On the surface, it reads as a logical engineering decision: a smart ring maker acquires the talent and technology to let users control devices with hand movements. But the purchase reveals something more significant about where the wearables industry believes it must go to survive.
The Finnish health technology company, valued at approximately USD 11 billion following its latest funding round, is no longer building a health tracker that happens to sit on your finger. It is deliberately shifting toward new forms of human-computer interaction as wearable devices evolve beyond passive health tracking, with gesture controls and voice inputs becoming central to how users will interact with Oura's smart rings in the future.
The move arrives at a critical moment for the category. The smart ring market saw shipments jump nearly 51% in 2025, with Oura leading the category. The company forecasts revenue exceeding USD 1.5 billion in 2026. Those numbers matter because they show explosive growth, but growth alone does not guarantee the business model survives intact.
Here's the genuine tension: Even using basic hardware features requires a paid subscription, according to recent product reviews. That creates friction. Users wearing a smart ring expect a frictionless experience; the form factor's entire appeal rests on its minimalism and invisibility. Asking those users to remember a subscription, manage an app, and navigate screens contradicts the whole premise.
Gesture recognition potentially solves this problem. If Oura can make hand movements feel natural and responsive, the ring transforms from a passive data collector you must actively consult into an intelligent interface that works in the background. That shift unlocks new revenue possibilities, which explains why Oura CEO Tom Hale sees it as a strategic priority. Oura believes the next phase of wearable AI will be powered by a combination of voice and gestures, and Doublepoint's expertise in AI, biometrics, and human-computer interaction accelerates its ability to power a broader ecosystem of ambient, privacy-first AI experiences.
Yet caution is warranted. The company purchased a firm called Proxy to bring biometric identity and payments technology to its devices in 2023; those features did not ship in the latest Oura Ring 4 released in 2024. Promises about future capabilities in wearables have a poor track record of near-term delivery. Oura's Chief Executive Officer cautioned that gestures would not happen "tomorrow or in the near term".
The broader competitive context matters too. Samsung released a Galaxy Ring in 2025 without a subscription model. Apple, while sceptical about standalone rings, continues to refine its ecosystem integration. Oura's acquisition strategy, now totalling four companies in two years, suggests legitimate concern about differentiation. Previous acquisitions included Proxy in 2023 to integrate biometric identity and payments technology, followed by metabolic health startup Veri and enterprise software company Sparta Science in 2024.
The economics of acquisition versus organic development deserve scrutiny. Rolling up multiple startups accelerates capability building but raises integration risks and dilutes focus. For a company built on precision health science, managing the cultural and technical complexity of four simultaneous absorptions is no trivial task.
That said, Oura's strategic instinct is sound. A ring sits on your finger all day, perfectly positioned to detect micro-movements that signal intent, and is invisible, always ready, and socially acceptable in contexts where pulling out a phone feels rude. If Oura can execute the gesture integration without introducing latency or requiring conscious thought, it genuinely does solve a genuine human problem about how we interact with ambient AI in an age when everyone carries a screen.
The smart ring market is real and growing. Whether Oura's subscription model and acquisition-heavy strategy will sustain that growth depends on execution. For investors and consumers watching this space, the Doublepoint deal signals seriousness about competing beyond health metrics. Whether that seriousness translates into a product customers actually prefer remains an open question that the next two years will answer.